Ribomic

Ribomic EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Ribomic (4591.T) as of Oct 30, 2026 is -1.45. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -1.38 — a change of 5.46% (lower).

EV/FCF

-1.45

YoY

5.46%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Ribomic is 2026 -1.45 . EV/FCF (Enterprise Value to Free Cash Flow) of Ribomic was 2025 -1.38 . It decreases by 5.46% lower compared to the previous year.

The Ribomic EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-3.59 JPY
Jan 1, 2020
-2.59 JPY
Jan 1, 2021
1.20 JPY
Jan 1, 2022
0.16 JPY
Jan 1, 2023
-0.08 JPY
Jan 1, 2024
-1.10 JPY
Jan 1, 2025
-1.38 JPY
Jan 1, 2026
-1.45 JPY
The Ribomic EV/FCF history
YEAREV/FCFYoY
-1.45+5.46%
-1.38+24.66%
-1.10+1,371.22%
-0.08-145.98%
0.16-86.41%
1.20-146.46%
-2.59-28.02%
-3.59+12.05%
-3.21+14.07%
-2.81-24.90%
-3.74-144.21%
8.47-140.88%
-20.72—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

EV/FCF (Enterprise Value to Free Cash Flow) of Ribomic is -1.45 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Ribomic changed from -1.38 to -1.45, representing a 5.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Ribomic since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Ribomic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Ribomic

All Key Metrics — Ribomic